Lieff Cabraser Enters Into Agreement with Scott County TN to Explore Opioid Epidemic Lawsuit

Opioid epidemic reaching epic proportions

Lieff Cabraser, with Knoxville-based Taylor and Knight, has entered into an official agreement with Scott County, Tennessee, to explore litigation against pharmaceutical companies and other parties over the pernicious opioid epidemic in Scott County. The decision, first announced by WBNT News, came via a unanimous 10-0 vote by the county legislature to begin investigation into lost revenues relating to the widespread distribution and use of pharmaceutical opioids in the county. [Read more…]

$300 Million Settlement in Benicar Litigation Over Drug Injury Claims

$300 Million Settlement in Benicar Litigation Over Drug Injury Claims

A $300 million settlement has been reached in the multidistrict Benicar litigation against Daiichi Sankyo Inc. and Forest Laboratories Inc. on claims that the top-selling blood pressure drug caused severe, and sometimes life-threatening, gastrointestinal injuries in users. [Read more…]

Congressional Bill HR 1215 Will Restrict Americans’ Rights to Obtain Justice in Medical Malpractice Cases

American Healthcare issues

Congress is about to vote on a bill that could restrict the rights of all Americans to obtain justice in our court system in cases of medical malpractice, including in cases involving negligent nursing homes and defective prescription drugs and medical devices. This bill would tip the scale against injured patients and their families in favor of the insurance industry and other large corporations. [Read more…]

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

On December 16, 2016, Chief Judge M. Casey Rodgers of the U.S. District Court for the Northern District of Florida issued an order appointing Lexi J. Hazam of Lieff Cabraser to the Plaintiffs’ Executive Committee in the multidistrict litigation previously consolidated in October 2016 over injuries and financial losses sustained by patients as a result of their use of the prescription drug Abilify. [Read more…]

Bristol-Myers Squibb Pays $19.5 Million Over Improper Abilify Drug Marketing

Bristol-Myers Squibb Pays $19.5 Million Over Improper Abilify Drug Marketing

Bristol-Myers Squibb has agreed to pay $19.5 million to settle claims of improper advertising relating to its top-selling drug Abilify. 42 states and Washington D.C. alleged that the company improperly advertised antipsychotic drug Abilify, first approved in 2002 by the FDA to treat schizophrenic in adults. However, Bristol-Myers Squibb thereafter began promoting Abilify for off-label uses not approved by the FDA. These off-label uses had not been established as safe or effective. [Read more…]

Abilify Gambling Lawsuits Consolidated in Florida Federal Court

Abilify Gambling Lawsuits Consolidated in Florida Federal Court

The Judicial Panel on Multidistrict Litigation has consolidated more than 20 lawsuits against Bristol-Myers Squibb Co. over claims of pathological gambling side effects in patients using the antipsychotic drug Abilify in federal court in Florida. The serious impulse-control problems described in the complaints reportedly stop when the medicine is discontinued. 22 actions pending in 12 districts will be centralized under Chief District Judge M. Casey Rodgers. [Read more…]

Study Finds Majority of Parents Give Their Children Wrong Dose of Liquid Medication

Study Finds Majority of Parents Give Their Children Wrong Dose of Liquid Medication

A study by various pediatric clinics located in New York, Atlanta, and California has discovered that the majority of parents unknowingly provide their children with the wrong dosage of liquid medication. This is occurring in part because despite pediatric medicines including a measuring tool with related instructions, often the units on the label – milliliters, mL, teaspoon, tsp., tablespoon – differ from what’s on the tools themselves. [Read more…]

Upcoming FDA Public Hearing on Off-Label Drug and Device Use

Upcoming FDA Public Hearing on Off-Label Drug and Device Use

The U.S. Food and Drug Administration (FDA) has announced a public hearing forum to take place on November 9-10, 2016 with regard to the enforcement of rules relating to off-label drug and medical product use in the public health industry. The registration deadline to present at the hearing is October 19, 2016, and the deadline for written commentary after the hearing is January 9, 2017. [Read more…]

Levaquin and Cipro, Secret Killers via Aneurysm, Aortic Dissection

female doctor examining a teenage girl in her office

Hundreds of Americans with Minor Infections Are Dying Every Year from Aneurysms That May Have Been Caused by the Super-Antibiotics they Should Never Have Been Prescribed

A class of strong antibiotic drugs including Levaquin and Cipro prescribed widely to treat common bacterial infections like urinary tract infections, bronchitis, and sinusitis have been linked to significantly increased risks of potentially life-threatening aortic aneurysms and aortic dissections. [Read more…]